Literature DB >> 29784643

The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma.

Leo Rasche1, Edgardo J Angtuaco2, Terri L Alpe1, Grant H Gershner1, James E McDonald2, Rohan S Samant2, Manoj Kumar2, Rudy Van Hemert2, Joshua Epstein1, Shayu Deshpande1, Ruslana Tytarenko1, Shmuel Yaccoby1, Jens Hillengass3, Sharmilan Thanendrarajan1, Carolina Schinke1, Frits van Rhee1, Maurizio Zangari1, Brian A Walker1, Bart Barlogie1, Gareth J Morgan1, Faith E Davies1, Niels Weinhold1.   

Abstract

Spatial intratumor heterogeneity is frequently seen in multiple myeloma (MM) and poses a significant challenge for risk classifiers, which rely on tumor samples from the iliac crest. Because biopsy-based assessment of multiple skeletal sites is difficult, alternative strategies for risk stratification are required. Recently, the size of focal lesions (FLs) was shown to be a surrogate marker for spatial heterogeneity, suggesting that data from medical imaging could be used to improve risk stratification approaches. Here, we investigated the prognostic value of FL size in 404 transplant-eligible, newly diagnosed MM patients. Using diffusion-weighted magnetic resonance imaging with background suppression, we identified the presence of multiple large FLs as a strong prognostic factor. Patients with at least 3 large FLs with a product of the perpendicular diameters >5 cm2 were associated with poor progression-free survival (PFS) and overall survival (OS; median, 2.3 and 3.6 years, respectively). This pattern, seen in 13.8% of patients, was independent of the Revised International Staging System (RISS), gene expression profiling (GEP)-based risk score, gain(1q), or extramedullary disease (hazard ratio, 2.7 and 2.2 for PFS and OS in multivariate analysis, respectively). The number of FLs lost its negative impact on outcome after adjusting for FL size. In conclusion, the presence of at least 3 large FL is a feature of high risk, which can be used to refine the diagnosis of this type of disease behavior and as an entry criterion for risk-stratified trials.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2018        PMID: 29784643      PMCID: PMC6034645          DOI: 10.1182/blood-2018-04-842880

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  31 in total

1.  Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition.

Authors:  Marc S Raab; Nicola Lehners; Jing Xu; Anthony D Ho; Peter Schirmacher; Hartmut Goldschmidt; Mindaugas Andrulis
Journal:  Blood       Date:  2016-02-16       Impact factor: 22.113

2.  Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma.

Authors:  Jens Hillengass; Kerstin Fechtner; Marc-André Weber; Tobias Bäuerle; Sofia Ayyaz; Christiane Heiss; Thomas Hielscher; Thomas M Moehler; Gerlinde Egerer; Kai Neben; Anthony D Ho; Hans-Ulrich Kauczor; Stefan Delorme; Hartmut Goldschmidt
Journal:  J Clin Oncol       Date:  2010-02-22       Impact factor: 44.544

3.  Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data.

Authors:  Sarah Waheed; Alan Mitchell; Saad Usmani; Joshua Epstein; Shmuel Yaccoby; Bijay Nair; Rudy van Hemert; Edgardo Angtuaco; Tracy Brown; Twyla Bartel; James McDonald; Elias Anaissie; Frits van Rhee; John Crowley; Bart Barlogie
Journal:  Haematologica       Date:  2012-06-24       Impact factor: 9.941

4.  Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma.

Authors:  S Mithraprabhu; T Khong; M Ramachandran; A Chow; D Klarica; L Mai; S Walsh; D Broemeling; A Marziali; M Wiggin; J Hocking; A Kalff; B Durie; A Spencer
Journal:  Leukemia       Date:  2016-11-30       Impact factor: 11.528

5.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

Authors:  Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

6.  High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH.

Authors:  J Shaughnessy; E Tian; J Sawyer; K Bumm; R Landes; A Badros; C Morris; G Tricot; J Epstein; B Barlogie
Journal:  Blood       Date:  2000-08-15       Impact factor: 22.113

7.  Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.

Authors:  Antonio Palumbo; Hervé Avet-Loiseau; Stefania Oliva; Henk M Lokhorst; Hartmut Goldschmidt; Laura Rosinol; Paul Richardson; Simona Caltagirone; Juan José Lahuerta; Thierry Facon; Sara Bringhen; Francesca Gay; Michel Attal; Roberto Passera; Andrew Spencer; Massimo Offidani; Shaji Kumar; Pellegrino Musto; Sagar Lonial; Maria T Petrucci; Robert Z Orlowski; Elena Zamagni; Gareth Morgan; Meletios A Dimopoulos; Brian G M Durie; Kenneth C Anderson; Pieter Sonneveld; Jésus San Miguel; Michele Cavo; S Vincent Rajkumar; Philippe Moreau
Journal:  J Clin Oncol       Date:  2015-08-03       Impact factor: 44.544

8.  Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumour mass and biology.

Authors:  Elias K Mai; Thomas Hielscher; Jost K Kloth; Maximilian Merz; Sofia Shah; Michaela Hillengass; Barbara Wagner; Dirk Hose; M S Raab; Anna Jauch; Stefan Delorme; Hartmut Goldschmidt; Marc-André Weber; Jens Hillengass
Journal:  Eur Radiol       Date:  2016-01-15       Impact factor: 5.315

9.  Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma.

Authors:  Y Jethava; A Mitchell; M Zangari; S Waheed; C Schinke; S Thanendrarajan; J Sawyer; D Alapat; E Tian; C Stein; R Khan; C J Heuck; N Petty; D Avery; D Steward; R Smith; C Bailey; J Epstein; S Yaccoby; A Hoering; J Crowley; G Morgan; B Barlogie; F van Rhee
Journal:  Blood Cancer J       Date:  2016-07-29       Impact factor: 11.037

10.  Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma?

Authors:  C Pawlyn; L Fowkes; S Otero; J R Jones; K D Boyd; F E Davies; G J Morgan; D J Collins; B Sharma; A Riddell; M F Kaiser; C Messiou
Journal:  Leukemia       Date:  2015-12-09       Impact factor: 11.528

View more
  25 in total

Review 1.  [Pathogenesis of multiple myeloma].

Authors:  L Rasche; N Weinhold
Journal:  Internist (Berl)       Date:  2019-01       Impact factor: 0.743

Review 2.  Molecular basis of clonal evolution in multiple myeloma.

Authors:  Yusuke Furukawa; Jiro Kikuchi
Journal:  Int J Hematol       Date:  2020-02-06       Impact factor: 2.490

Review 3.  Toward personalized treatment in multiple myeloma based on molecular characteristics.

Authors:  Charlotte Pawlyn; Faith E Davies
Journal:  Blood       Date:  2018-12-26       Impact factor: 22.113

4.  Meeting report of the 7th Heidelberg Myeloma Workshop: today and tomorrow.

Authors:  M A Baertsch; R Lutz; M S Raab; N Weinhold; H Goldschmidt
Journal:  J Cancer Res Clin Oncol       Date:  2019-08-12       Impact factor: 4.553

Review 5.  Progress of modern imaging modalities in multiple myeloma.

Authors:  Toshiki Terao; Kosei Matsue
Journal:  Int J Hematol       Date:  2022-05-09       Impact factor: 2.490

Review 6.  [Potential of radiomics and artificial intelligence in myeloma imaging : Development of automatic, comprehensive, objective skeletal analyses from whole-body imaging data].

Authors:  Markus Wennmann; Jacob M Murray
Journal:  Radiologe       Date:  2021-12-10       Impact factor: 0.635

Review 7.  Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

Authors:  Sarah A Holstein; Zaid Al-Kadhimi; Luciano J Costa; Theresa Hahn; Parameswaran Hari; Jens Hillengass; Allison Jacob; Nikhil C Munshi; Stefania Oliva; Marcelo C Pasquini; Qian Shi; Edward A Stadtmauer; Stephanie L Waldvogel; Philip L McCarthy
Journal:  Biol Blood Marrow Transplant       Date:  2019-09-14       Impact factor: 5.742

Review 8.  A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration.

Authors:  Christian M Schürch; Leo Rasche; Leonie Frauenfeld; Niels Weinhold; Falko Fend
Journal:  Virchows Arch       Date:  2019-12-17       Impact factor: 4.064

9.  Quantitative whole-body MR imaging for assessment of tumor burden in patients with multiple myeloma: correlation with prognostic biomarkers.

Authors:  Mengtian Sun; Jingliang Cheng; Cuiping Ren; Yong Zhang; Yinhua Li; Ying Li; Suping Zhang
Journal:  Quant Imaging Med Surg       Date:  2021-08

10.  Whole Body Low Dose Computed Tomography (WBLDCT) Can Be Comparable to Whole-Body Magnetic Resonance Imaging (WBMRI) in the Assessment of Multiple Myeloma.

Authors:  Davide Ippolito; Teresa Giandola; Cesare Maino; Davide Gandola; Maria Ragusi; Pietro Andrea Bonaffini; Sandro Sironi
Journal:  Diagnostics (Basel)       Date:  2021-05-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.